Immutep (IMM) AGM 2024 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional land owners, introduction of board members and key executives, and confirmation of quorum and voting procedures.

• Notice of meeting confirmed as distributed and taken as read.

• Presentation focused on business updates, clinical progress, and strategic outlook, covering company overview, highlights, Efti and IMP761 programs, and summary.

Financial performance review

• Raised AUD 100.2 million ($63 million) via a fully underwritten equity issue, closing FY24 with AUD 181.8 million in cash and equivalents.

• Cash and equivalents totaled A$172.3 million as of 30 September 2024, following a significant equity raise in June 2024.

• Total revenue and other income reached A$7.8 million in FY24, up from A$5.2 million in FY23.

• R&D and IP expenses increased to A$41.5 million in FY24, driven by expanded clinical trial activity, while G&A expenses remained stable.

• Financial strategy described as disciplined and growth-oriented, providing a runway to end of 2026.

Board and executive committee updates

• Dr. Frédéric Triebel re-elected as director, with remarks on upcoming announcements and the company's positioning as a phase III company.

• Performance rights approved for CEO Marc Voigt and CSO Dr. Triebel under the executive incentive plan.